Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, April 23rd:Fortuna Silver Mines Inc. (FSM) : This miner of precious and base metals has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 66.7% over the last 60 days.Fortuna’s shares gained 46.8% over the last three months compared with the S&P 500’s advance of 2.2%. The company possesses a Momentum Score  of A.Louisiana-Pacific Corporation (LPX) : This m ...

Erasca, Inc. (NASDAQ:ERAS) R&D Update Call and Q4 2023 Earnings Conference Call March 28, 2024 8:30 AM ET Company Participants Jonathan Lim - Chairman, CEO & Co-founder Shannon Morris - Chief Medical Officer David Chacko - CFO & Chief Business Officer Conference Call Participants Anupam Rama - JP Morgan Michael Riad - Morgan Stanley Alec Stranahan - Bank of America Merrill Lynch Andres Maldonado - HC Wainwright & Co. Jonathan Miller - Evercore ISI Graig Suvannavejh - Mizuho Securities Chris Shibutani - Gold ...

SAN DIEGO, March 27, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS) ("Erasca"), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors to sell 21,844,660 shares of its common stock in an oversubscribed private placement at a price of $2.06 per share. Erasca a ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended DECEMBER 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40602 ERASCA, INC. (Exact name of Registrant as specified in its Charter) | Delaware | | 83-1217027 | | --- | --- | --- | | (State or ...

Exhibit 99.1 Erasca Reports Fourth Quarter 2023 and Full Year 2023 Business Updates and Financial Results Gained global registrational clarity for naporafenib and achieved key clinical milestones for naporafenib, ERAS- 007, and ERAS-801 Multiple data readouts expected in 2024 for naporafenib (SEACRAFT-1), ERAS-007 (HERKULES-3), and ERAS-801 (THUNDERBBOLT-1) and planned initiation of pivotal SEACRAFT-2 trial Robust balance sheet with cash, cash equivalents, and marketable securities of $322 million as of Dec ...

Naporafenib is a potential first-in-class and best-in-class pan-RAF inhibitor in multiple RAS/MAPK pathway-driven tumors Initial SEACRAFT-1 Phase 1b combination data in RAS Q61X solid tumors expected between Q2-Q4 2024 Initiation of pivotal SEACRAFT-2 in NRASm melanoma expected in H1 2024 SAN DIEGO, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Erasca, Inc. (NASDAQ:ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to ______________ Commission File Number: 001-40602 ERASCA, INC. (Exact Name of Registrant as Specified in its Charter) (State or other jurisd ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to ______________ Commission File Number: 001-40602 ERASCA, INC. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdictio ...

FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _____________ to ______________ Commission File Number: 001-40602 ERASCA, INC. (Exact Name of Registrant as Specified in its Charter) (State or other jurisdicti ...

234 55 55 35 225 120 260 126 10 ERAS-3490 56 1,221 1,687 483 Erasca's naporafenib pan-RAFi could address unmet needs P P P Autophagy MAPK pathway ULK PI3K pathway RAS-GTP GRB2 SHP2 GAP GDP GTP P1 NF1 SOS1 RAF MEK PI3K AKT mTOR RAS-GDP EGFR/ Other FLT3 RTKs MYC GEF ERK naporafenib BRAF CRAF RAS Q61X Solid Tumors 157,000 NRASm Melanoma 54,000 NF1 Loss-of-Function 234,000 BRAF Class II/III Solid 55,000 11 | --- | --- | |--------------------------------------|------------| | Assay | Value (nM) | | Biochemical C ...